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Edited by Ivan SadowskiAbstract For suicide gene therapy to be successfully applied for
clinical settings, cancer-restricted expression of such suicide gene
should be required. We previously showed that group I intron
from Tetrahymena can induce new RNA that exerts anti-cancer
activity through RNA replacement by trans-splicing reaction
with high ﬁdelity and speciﬁcity onto targeted human telomerase
reverse transcriptase (hTERT) RNA in cancer cells, and hence
the ribozyme can selectively retard growth of the cells in vivo
as well as in vitro. However, the shortage of complete tumor-
selectivity due to telomerase expression of highly proliferating
normal cells can limit therapeutic applicability of the hTERT-
targeting approach. In this study, to explore the possibility of
improving speciﬁcity of cancer therapy, we have attempted to
stimulate anticancer gene activity speciﬁcally in liver cancer cells
by tissue-speciﬁc expression of the hTERT-targeting trans-splic-
ing ribozyme using liver-speciﬁc promoters. Transient transfec-
tion experiments demonstrated that the expression of transgene
such as luciferase gene was speciﬁcally and highly triggered from
hTERT-expressing liver cancer cells transfected with the ribo-
zyme. Moreover, liver-speciﬁc expression of the ribozyme with
diphtheria toxin A or herpes simplex virus thymidine kinase gene
as 3 0 exon could speciﬁcally and highly retard the growth of the
hTERT-expressing liver cancer cells. In conclusion, we can
greatly improve speciﬁcity of cancer cytotoxicity by combination
of transcriptional targeting for tissue-speciﬁc transgene expres-
sion with RNA replacement for cancer-speciﬁc anticancer gene
induction.
 2006 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Hepatocellular carcinoma is one of the most common malig-
nant diseases with a poor prognosis throughout the world be-
cause it frequently recurs shortly after surgical or nonsurgical
treatments [1,2]. This is because tumor cells can survive evenAbbreviations: hTERT, human telomerase reverse transcriptase;
ApoE, apolipoprotein E; PEPCK, phosphoenolpyruvate carboxy-
kinase; Alb, serum albumin; HSV-tk, herpes simplex virus thymidine
kinase; GCV, ganciclovir; DT, diphtheria toxin A; Fluc, ﬁreﬂy lucif-
erase
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doi:10.1016/j.febslet.2006.08.021after combined treatments and progress to locally recurrent
and distant metastatic lesions. To overcome these clinical
problems, newly established treatments, such as gene therapy,
can be combined with the conventional treatments.
For the success of gene therapy in clinical settings, develop-
ment of control system of transgene expression combined with
tissue-speciﬁc gene delivery systems should be considered. Sui-
cide gene therapy under the control of strong constitutive viral
promoters such as CMV, RSV, or SV40 promoter is an eﬀec-
tive strategy in cancer treatment. However, its use, especially
for the treatment of liver malignancies, is severely limited by
organ toxicity due to no current technique for the reliable
transduction of 100% of speciﬁc cells in vivo [3–7]. Therefore,
development of modulated gene expression system such as
tumor-restricted gene expression through transcriptional tar-
geting without aﬀecting normal cells is required.
One such approach is to restrict expression of the transgene
to the target organ. In liver, this has been achieved using the
tissue-speciﬁc promoter of the apolipoprotein E (ApoE), phos-
phoenolpyruvate carboxykinase (PEPCK), or serum albumin
(Alb), etc. ApoE has a major role in the redistribution of cho-
lesterol and other lipids between peripheral tissues and the
liver [8]. The highest level of ApoE gene expression occurs in
the liver, which accounts for as much as 90% of their circulat-
ing levels in the plasma [9]. The ApoE gene is expressed at
moderate levels in tissues such as in the skin or brain, and
much lower expressed in several other tissues, including the
kidney [10]. PEPCK catalyzes a rate-controlling step of gluco-
neogenesis, the process by which cells synthesize glucose from
metabolic precursors [11]. PEPCK gene expression is highest in
liver [12], but signiﬁcant expression also occurs in the other
gluconeogenic organ, the kidney [13]. PEPCK promoter signif-
icantly activates the level of transcriptional induction pro-
duced by liver-enriched transcription factors in hepatoma
cells [12]. Alb is probably the most characteristic protein syn-
thesized by the mature liver, accounting for more than 10%
of total protein synthesis [14]. The albumin gene promoter thus
provides a paradigm for regulation of transcription in the ter-
minally diﬀerentiated hepatocytes. The albumin promoter was
used to direct liver-speciﬁc expression [15,16]. Therefore, ther-
apeutic vectors targeting liver tissue are currently generated
using such tissue-speciﬁc promoters: however, this technique
is still limited due to the lack of tumor speciﬁcity.
Recently, we developed cancer speciﬁc RNA-targeting trans-
splicing ribozyme as a new anti-cancer agent which can specif-
ically induce transgene activity in cancer cells [17]. These
ribozymes are based on the group I intron of the large
ribosomal RNA subunit of Tetrahymena thermophila asblished by Elsevier B.V. All rights reserved.
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verse transcriptase (hTERT) RNA-targeting speciﬁc trans-
splicing ribozyme directed the expression of therapeutic genes
with high ﬁdelity and speciﬁcity in telomerase-positive cancer
cells via targeted RNA replacement of the hTERT transcript,
which could selectively and speciﬁcally retard the growth of the
tumor cells not only in culture but in vivo [17]. This ribozyme,
Rib21AS, speciﬁcally targeted +21 nucleotide position of
hTERT transcript, which was found most accessible to group
I-based ribozymes. The eﬃcacy and speciﬁcity of the ribozyme
was improved by modiﬁcation of internal guide sequence
(IGS) such as extension of P1 helix, and addition of P10 helix
and 300 bp long antisense domain against downstream
sequence of the targeted hTERT region [17] (Fig. 1). However,
one concern about such hTERT-targeting approach to can-
cer therapy is the shortage of complete tumor-selectivity
because highly proliferating normal cells are also telomerase-
positive.
In this study, to explore the possibility of improving speciﬁc-
ity of cancer therapy, we have attempted to combine transcrip-
tional targeting using liver-speciﬁc promoter for tissue-speciﬁc
transgene expression with RNA replacement using trans-splic-
ing ribozyme for cancer-speciﬁc transgene induction (Fig. 1).
We have shown that expression of the hTERT targeting
trans-splicing ribozyme with the ApoE or PEPCK promoter
leaded to selective suppression of the growth of human liver
cancer cells. However, expression of the ribozyme under the
liver-speciﬁc promoters caused much less regression of not
only normal liver cells but also cancer cells with other tissue
origin including ovarian cancer, cervical cancer, or erythro-
leukemia cells.2. Materials and methods
2.1. Cell cultures
Table 1 describes the cell lines utilized in this study. The human cell
line SK-HEP-1, SK-OV-3, HT-29, AGS and HeLa were maintained in
DMEM with 10% heat-inactivated fetal bovine serum (FBS; Jeil Bio-
techservices Inc.). HepG2, Hep3B, ACC, DU145, and IMR-90 were
cultured in EMEM (Invitrogen) with 10% FBS. SNU398, MCF7
and TF-1a cells were grown in RPMI 1640 (Invitrogen) supplemented
with 10% FBS. THLE-3 was cultured in bronchial/tracheal epithelial
cell growth medium (Cambrex) with 10% FBS, 6.5 ng/ml triiodothyro-
nine, 50 lg/ml gentamycin, and 50 ng/ml amphotericin-B.Fig. 1. Schematic diagram of hTERT-targeting trans-splicing ribozyme deriv
the hTERT mRNA and the ribozyme expressed from the liver-speciﬁc pro
shown, and helices P1 (white box) and P10 (gray box) are indicated together
show 5 0 and 3 0 splice site. Dark arrow represents liver-speciﬁc promoters
ribozyme.2.2. Expression constructs
The pSV40-Fluc vector, which contains ﬁreﬂy luciferase gene (Fluc)
controlled by a SV40 promoter, was generated in the previous study
[17]. The phgApoEex, pPEPCK-LCR, and pAlbex 1.0 vectors, which
harbor liver-speciﬁc promoters and enhancers, were gifts from
Dr. K. Oka (Baylor College of Medicine). The Fluc cDNA was
inserted into the NotI site present in the downstream of each liver-spe-
ciﬁc promoter to generate pApoE-Fluc, pPEPCK-Fluc, or pAlb-Fluc.
pSV40-Rib21AS-Fluc encoding hTERT-targeting trans-splicing ribo-
zyme plus Fluc as 3 0 exon was constructed from the previous study
[17]. DNA fragments encompassing Rib21-Fluc or Rib21AS-Fluc se-
quence were inserted into the NotI cloning site of each liver-speciﬁc
vector to generate expression vectors for the ribozyme under the
liver-speciﬁc promoters shown in Fig. 3A. The Fluc cDNA in each
liver-speciﬁc vector was replaced with diphtheria toxin A (DT) or her-
pes simplex virus thymidine kinase (HSV-tk, TK) cDNA to construct
liver-cancer targeting speciﬁc vectors shown in Figs. 4A and 6A.
2.3. Luciferase assay
The reporter gene constructs encoding Fluc under diﬀerent promot-
ers were transiently co-transfected with phRL-CMV (Promega), which
encodes Renillar luciferase under CMV promoter and is used for nor-
malization of transfection eﬃciency, into cell lines described in Table 1
using Lipofectamin (Invitrogen), DMRIC-C (Invitrogen), or Exgen
(MBI Fermentas) according to the suppliers protocol. The best trans-
fectant reagent and the transfection eﬃciency into each cell line were
determined using the GFP-encoding plasmid as described in Table 1.
After transfection, cells were plated into 35 mm dishes, incubated fur-
ther for 24 h in appropriate media. Cells were lysed and luciferase
activity was determined by chemiluminescense in luminometer TD-
20/20 (Turner Designs Instrument) using dual-luciferase reporter assay
system (Promega).
2.4. Cell toxicity assay
Cells described above were seeded in 6-well plates at a density of
3.0 · 105 cells/well. The next day, cells were transfected with 1 lg of
expression vector encoding DT gene and 250 ng of pEGFP-N1 encod-
ing GFP under CMV promoter (Clontech) with best transfectant
reagent for each cell described in Table 1. Cell toxicity assays were
performed 48 h after transfection using a ﬂuorescence microscopy.
Cells in 30–50 random ﬁelds of view were analyzed, and the number
of GFP-expressing cells was counted under ﬂuorescence microscopy.
Absolute cell counts were conﬁrmed by counting on AlphaEase FC
software (Alpha Innotech).
2.5. Suicide gene activity assays
Cells were plated one day before the transfection in suitable media.
pEGFP-N1 (250 ng) was co-transfected with pApoE-Rib21AS-TK,
pPEPCK-Rib21AS-TK, or pSV40-Rib21AS-TK (1 lg), or pSV40-Rib-
21AS-Fluc (1 lg). Twenty four hour after transfection, 100 lM ganci-
clovir (GCV; Cymevene, Roche) was added to each plate, and then
the cells were further incubated for three days. The surviving cells wereed by liver-speciﬁc promoters. The base-pairing was presented between
moters or SV40 promoter. Target and ribozyme RNA sequences are
with the 300 nucleotide long complementary region (antisense). Arrows
or SV40 promoter utilized for intracellular expression of the speciﬁc
Table 1
Description of cell lines used in this study and transfection reagent and eﬃciency in each cell line
Cell line Transfection
reagent (%d)
Description
Liver cancer Tel+e HepG2 Exa 11 Human hepatocellular carcinoma cells (ATCC no. HB-8065)
Hep3B Ex 8 Human hepatocellular carcinoma cells (ATCC no. HB-8064)
SNU398 Lipob 0.3f Human hepatocellular carcinoma cells (ATCC no. CRL-2233)
SK-Hep-1 Lipo 5 Human liver adenocarcinoma cells (ATCC no. HTB-52)
Non-liver cancer Tel+e SK-OV-3 Lipo 19 Human ovary adenocarcinoma cells (ATCC no. HTB-77)
MCF7 Ex 23 Human breast adenocarcinoma cells (ATCC no. HTB-22)
HT-29 Ex 2.6 Human colorectal adenocarcinoma cells (ATCC no. HTB-38)
ACC Ex 13 Human neuronal cancer cells (obtained from C.H. Chung at the
Yonsei Medical Center, Korea)
DU145 Lipo 4 Human prostate carcinoma cells (ATCC no. HTB-81)
AGS Ex 21 Human gastric adenocarcinoma cells (ATCC no. CRL-1739)
HeLa Lipo 13.5 Human cervix adenocarcinoma cells (ATCC no. CCL-2)
TF-1a DMc 0.1f Human erythroleukemia cells (ATCC no. CRL-2451)
Tele IMR-90 Ex 20.6 Normal human lung embryo ﬁbroblast (ATCC no. CCL-186)
Nontumorigenic liver THLE-3 Lipo 37 SV40 large T antigen immortalized primary normal liver cells (CRL-11233)
aEx, exgen.
bLipo, lipofectamin.
cDM: DMRIC-C.
dTransfection eﬃciency, percentage of GFP-positive cells when transfection with pEGFP-N1 vector.
eTelomerase activity level was determined by the TRAP assay [32].
fBecause of this low transfection eﬃciency, ribozyme activity was assessed more than six times for exclusion of statistical misleading in the cells.
Moreover, cells in more than 50 random ﬁelds of view were analyzed for each experiment.
Fig. 2. Speciﬁcity and strength of tissue-speciﬁc promoters. Three liver-speciﬁc promoter constructs were transfected onto the indicated telomerase-
positive (Tel+) or telomerase-negative (Tel) cell lines. NT means non-tumorigenic cells. Luciferase activity in each plasmid is represented as a
percentage of that of the positive control plasmid, pSV40-Fluc. Results represent the means ± S.D. of three to six independent experiments.
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fected cell. Cell viability after GCV treatment was quantiﬁed as the
fraction of GFP positive cells without GCV. All data were measured
in at least three to six separate experiments.3. Results
3.1. Analysis of the tissue-speciﬁc promoter activity
To evaluate the tissue speciﬁcity and the level of transcrip-
tional activity by the diﬀerent liver-speciﬁc promoters includ-
ing ApoE, PEPCK, and Alb, luciferase gene assays were
performed. Four tumor cell lines derived from human liver
carcinomas (HepG2, Hep3B, SNU398, SK-Hep-1), several
tumor cell lines of non-liver origin (SK-OV-3, MCF7, HT-
29, ACC, DU145, AGS, HeLa, TF-1a), telomerase negative
cell line (IMR90), or nontumorigenic liver cell line (THLE3)
were transiently transfected with pApoE-Fluc. pPEPCK-Fluc,pAlb-Fluc, or pSV40-Fluc. The Fluc activity driven by each
liver-speciﬁc promoter was expressed as a percentage of that
mediated by the SV40 promoter-driven construct (Fig. 2). In
Hep3B, three liver speciﬁc promoters were more active than
the SV40 promoter. In most liver cell lines, ApoE and PEPCK
promoters were similar to or more active than the SV40
promoter. Moreover, substantial Fluc gene expression from
liver-speciﬁc promoters was observed in THLE3, which is
immortalized but non-tumorigenic normal liver cells. Much
lower activity was found with the liver-speciﬁc promoter con-
structs in most of non-liver cancer cell lines (SK-OV-3, HT-29,
ACC, DU145 and TF-1a). However, in several cell lines such
as MCF7, AGS, HeLa cells, or telomerase negative IMR90
cells, high reporter activity was shown by the PEPCK pro-
moter (about 80% relative to the SV40 promoter activity).
These results are in good accordance to the previously pub-
lished data with liver speciﬁc promoters [10,12,16]. This sug-
gests that the observed liver-speciﬁc promoters harbor high
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cancer cell lines, but they can induce non-speciﬁc gene expres-
sion also in several cancer cells with non-liver origin.
3.2. Speciﬁc induction of Fluc gene activity by hTERT-targeting
trans-splicing ribozyme driven by liver-speciﬁc promoters
Transcriptional targeting utilizing liver-speciﬁc promoters
exploits promoter and/or enhancer sequences of genes that
are switched on highly in certain livers. However, one of the
main limitations of this type of promoter is that expression
of transgene with cytocidal activity may lead to cytotoxin ef-
fects in normal as well as tumor tissue derived from that same
cell type. In other words, dilemma of the transcriptional target-
ing is how to achieve high levels of transgene expression with-
out compromising speciﬁcity in hepatocarcinoma.
Recently, we developed hTERT RNA-targeting speciﬁc
trans-splicing ribozyme as an anti-cancer agent that can induce
transgene activity selectively in cancer cells as described in Sec-
tion 1. In this study, we constructed liver-speciﬁc expression
systems of the trans-splicing ribozyme using the liver-speciﬁc
promoters to improve tissue speciﬁcity of anticancer activity
by the ribozyme.
The eﬃcacy and speciﬁcity of the liver-speciﬁc promoters to
drive ribozyme expression was tested in variant cell lines de-Fig. 3. Functional analysis of liver-speciﬁc expression system of the speci
expressing constructs. Abbreviations: hTERT AS, hTERT antisense; Rib,
region; HCR1, hepatic control region 1. (B) Activity of the ribozyme in liv
ribozyme in non-liver cell lines. For comparison, the Fluc activities by the liv
by SV40 promoter-driven ribozyme. Each experiment was performed three tscribed in Fig. 2. The schematic representation of ribozyme-
expressing vectors used on this study was depicted in
Fig. 3A. If both ribozymes and hTERT RNA are well ex-
pressed in the cells, the ribozymes could elicit 3 0 exon activity,
luciferase activity, via trans-splicing reaction with the hTERT
RNA. The activity of diﬀerent promoters (ApoE, PEPCK,
Alb, or SV40) was assessed in liver or non-liver cell lines by
luciferase reporter assay. We quantiﬁed the Fluc activities trig-
gered by the trans-splicing ribozyme driven by the liver-speciﬁc
promoters as a percentage of those by the SV40 promoter in
each cell (Fig. 3B or C).
As shown in Fig. 3B, in liver cell lines, the Fluc activity
driven by pApoE-Rib21AS-Fluc was higher than pSV40-
Rib21AS-Fluc. Especially, both pApoE-Rib21AS-Fluc and
pApoE-Rib21-Fluc constructs showed so much higher lucifer-
ase activities like 4890% and 3292%, respectively, of the activ-
ity caused by SV40 promoter construct. This could be due to
accumulation of ribozymes from these expression cassettes to
signiﬁcantly higher levels (30-fold more, data not shown)
than the ribozymes from the SV40 promoter, yielding much
higher amount of trans-spliced products. Higher expression
of trans-splicing ribozymes was observed to enhance level of
RNA repair activity of the ribozymes in cells, as described
[19]. Activity by pPEPCK-Rib21AS-Fluc was high as almostﬁc ribozyme in human cells. (A) Schematic illustration of ribozyme-
trans-splicing ribozyme; F.luci., ﬁreﬂy luciferase; LCR, locus control
er cell lines. NT represents nontumorigenic cells. (C) Activity of the
er speciﬁc promoter-driven ribozymes were quantiﬁed relative to those
o six times and average was presented with S.D.
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noma cell. Although ApoE promoter was active as the same
level as SV40 promoter in HeLa cells, liver-speciﬁc promoters
showed low expression level of luciferase gene not exceeding
50% of the level by SV40 promoter in most of non-liver cell
lines (Fig. 3C). The pAlb-Rib21AS-Fluc plasmid was far less
eﬀective as ribozyme expression vector even in liver cancer
cells. These indicate that ApoE and PEPCK promoters are
suitable liver-speciﬁc promoters for ribozyme expression in
liver cell lines. However, pApoE-Rib21AS-Fluc transfectant
was shown to have Fluc activity up to 220% of that from
SV40 promoter in non-tumorigenic normal cells, THLE3.
When cytotoxic genes are utilized to speciﬁcally eradicate can-
cer cells, the transgenes will be detrimental if unintentionallyFig. 4. Analysis of liver cancer-speciﬁc induction of DT activity by the spec
constructs containing liver-speciﬁc promoter/enhancer, antisense region aga
viability was assessed by counting the number of GFP-positive cells in 30–50
vector and represented as % relative to the number of control vector-transfec
in normal telomerase-negative IMR90 cells or nontumorigenic (NT) liver ce
Rib21AS-DT (C), or pSV40-Rib21AS-Fluc and pAlb-Rib21AS-DT (D). Fold
DT in telomerase-positive liver cancer cell lines (E) or non-liver cancer cell li
Values are expressed as means ± S.D. from three to six independent experimexpressed in normal cells. For that reason, the ApoE promoter
was probably not useful to achieve safety. On the contrary,
when the pPEPCK-Rib21AS-Fluc plasmid was transfected
into the THLE3 cells, less expression of Fluc was observed.
In addition, there was minimal expression in the IMR90 (telo-
merase non-expressing cell line). Importantly, Fluc induction
activity by the ribozyme expressed from PEPCK promoter
was low in general in the non-liver cell lines, compared with
that by the ribozyme expressed from SV40 promoter
(Fig. 3C). This is due to lower expression of the ribozyme by
PEPCK promoter in those cells (data not shown). It should
be noticed that Fluc expression was hardly observed in the
telomerase-positive TF-1a cells, which originated from the
bone marrow cells of erythroleukemia patients [20].iﬁc ribozyme expressed from the liver-speciﬁc promoters. Structure of
inst hTERT, ribozyme speciﬁc to hTERT RNA, and DT (A). Cell
random ﬁelds after transient transfection with each ribozyme-encoding
ted GFP-positive cells. Cell viability by each ribozyme-encoding vector
ll lines (B). Cell viability in telomerase-positive cancer cells by pSV40-
increase of cell survival by pApoE-RibAS-DT or pPEPCK-RibAS21-
nes (F), when compared with the cell survival by pSV40-Rib21AS-DT.
ents.
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liver cancer cells by the speciﬁc ribozyme
To test the liver cancer-speciﬁc cytotoxicity by the hTERT-
targeting ribozyme derived by the liver-speciﬁc promoters, tran-
sient co-transfection experiments were performed with plasmids
expressing the ribozymewithDT as its 3 0 exon under the controlTable 2
Survival cell percentage by DT-encoding trans-splicing ribozymes
Vector Liver cancer (Tel+)
HepG2 Hep3B SNU398
pSV40-Rib21AS-DT 22 27 29
pAPO-Rib21AS-DT 54 27 15
pPEPCK-Rib21AS-DT 39 39 81
Non-liver cancer (Tel+)
SK-OV-3 MCF7 HT29
pSV40-Rib21AS-DT 26 11 29
pAPO-Rib21AS-DT 67 34 79
pPEPCK-Rib21AS-DT 107 62 52
The number of GFP-positive cells after transfection with DT-encoding speci
with control vector, pSV40-Fluc. Values are expressed as averages from thre
Fig. 5. Cytotoxicity by the speciﬁc ribozymes with DT in telomerase-positiv
expression levels was performed using AxioCam HR4 version 5.05.10. Zeiss m
identical parameters for excitation and detection were used.of the constitutive SV40 promoter (pSV40-Rib21AS-DT), the
ApoE promoter(pApoE-Rib21AS-DT), the PEPCK promoter
(pPEPCK-Rib21AS-DT), or the Alb promoter (pAlb-Rib-
21AS-DT) in the variable cell lines (Fig. 4A). The co-transfected
reporter plasmid, pEGFP-N1, contained the enhanced green
ﬂuorescent protein gene driven by the CMV promoter. WhenTel Non-tumorigenic liver
SK-Hep-1 IMR90 THLE3
16 99 97
45 97 98
38 99 101
ACC DU145 AGS HeLa TF-1a
12 23 18 30 18
24 35 59 60 101
55 46 46 94 149
ﬁc ribozyme vectors was indicated as a percentage of those transfected
e to six independent experiments.
e liver cancer cells (A) or non-liver cancer cells (B). Analysis of GFP
icroscope. For comparison of expression levels between preparations,
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the ribozymes will induce DT activity via trans-splicing with the
hTERTRNA, causing cell cyotoxicity. DT activity was inferred
from the reduction of GFP activity caused by expression of the
DT-harboring ribozyme using a modiﬁcation of the strategy
previously described [17,21].
As previously observed [17], every construct was very inac-
tive to induce cytotoxicity in telomerase-negative IMR90 or
nontumorigenic THLE3 cells (Fig. 4B). By contrast, cell cyto-
toxicity was proportional to the strength of the SV40 promoter
if the cells are telomerase-positive [22,23] (Fig. 4C and data not
shown). As control, the pSV40-Rib21AS-Fluc had little cyto-
toxic activity, and pAlb-Rib21AS-DT induced the lowest tox-
icity in all cell types among the DT-encoding ribozyme vectors
(Fig. 4D). Cell viability by pApo-Rib21AS-DT or pPEPCK-
Rib21AS-DT increased much higher in non-liver cancer cell
lines (2–10-fold) than in liver cancer cell lines (62-fold) when
compared with pSV40-Rib21AS-DT (Fig. 4E or F). The
number of GFP-positive cells in the pApo-Rib21AS-DT or
pPEPCK-Rib21AS-DT transfected cells relative to that in
the control vector-transfected cells was presented in Table 2.
As shown, ribozymes from both liver-speciﬁc promoters eﬃ-
ciently reduced cell viability up to 85% in telomerase-positive
liver cancer cells. However, cytotoxicity by the ribozyme ex-
pressed from ApoE or PEPCK promoter was much decreased
in telomerase-positive non-liver cancer cells when comparedFig. 6. Analysis of liver cancer-speciﬁc induction of TK activity by the hTER
promoters in normal liver, hepatocarcinoma, or non-liver cancer cells. Const
with TK gene (A). Cell viability in normal telomerase-negative IMR90 cell
ribozyme-encoding vector and GCV treatment (B). The viability was represe
GCV treatment in telomerase-positive cancer cells by pSV40-Rib21AS-TK (
RibAS21-TK after GCV treatment in telomerase-positive liver cancer cell lin
survival by pSV40-Rib21AS-TK. Values are expressed as averages ± S.D. frwith SV40 promoter-derived ribozyme. Especially, cytotoxicity
was hardly induced in ovarian cancer, cervical cancer, or erythro-
leukemia cells by the ribozymes from the PEPCK promoter,
which is in accorded with the Fluc induction results (Table
2). These results suggest that the activity of ApoE and PEPCK
promoters is signiﬁcantly higher in liver cancer cells than in
non-liver cancer cells, and the speciﬁc ribozyme expressed from
both promoters can speciﬁcally and eﬃciently induce cytotox-
icity of telomerase-positive liver cancers.
Representative features of cytotoxicity by expressing DT-
harboring ribozymes with liver-speciﬁc or SV40 promoter were
shown in Fig. 5. Although Alb promoter was not proper for
eﬃcient expression of the speciﬁc ribozyme even in liver can-
cers, ribozymes expressed from ApoE or PEPCK promoter
could eﬀectively induce cytotoxicity in the liver cancer cells
including HepG2 and Hep3B, which level is comparable to
the cytotoxicity by SV40 promoter (Fig. 5A). In contrast, the
ribozymes from the liver-speciﬁc promoters could stimulate
much less level of cytotoxicity in non-liver cancers such as
ovarian, breast, or neuronal cancer cells, when compared with
SV40 promoter (Fig. 5B).
3.4. Selective induction of suicide gene activity in telomerase-
positive liver cancer cells by the speciﬁc ribozyme
Although use of DT gene has an advantage for the analysis
of cancer cell cytotoxicity in that its activity can be simplyT-speciﬁc ribozyme. The ribozyme was expressed from the liver-speciﬁc
ruct of liver-speciﬁc expression vectors of the speciﬁc ribozyme tagged
s or nontumorigenic (NT) liver cell lines after transfection with each
nted as % relative to that of mock-transfected cells. Cell viability with
C). Fold increase of cell survival by pApoE-RibAS-TK or pPEPCK-
es (D) or non-liver cancer cell lines (E), when compared with the cell
om three to six independent experiments.
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ter expression due to inhibition in protein synthesis [21], direct
use of the A-fragment of DT will be not appropriate for cancer
treatment because of its highly toxic eﬀects when introduced
into the cytoplasm of eukaryotic cells. One strategy to circum-
vent this limitation is to employ the delivery to tumor cells of
genes encoding prodrug-converting enzyme such as HSV-tk
and then treatment with systemic administration of the respec-
tive nontoxic prodrug such as GCV. HSV-tk, unlike its mam-
malian homologues, eﬃciently converts the innocuous
nucleoside analog, GCV, into a phosphorylated form that
interferes with normal DNA replication and other cellular
functions [24].Fig. 7. Selective cytotoxicity of hepatocarcinoma cells with GCV treatment
The indirect assessment of cell death was employed with analysis of GFP gen
(C). Mock transfected cells showed no detrimental eﬀect after GCV treatm
SKOV3 cells transfected with each construct and administered with GCV.To test how much the ribozyme driven by liver-speciﬁc
promoters could speciﬁcally induce TK gene activity and cell
toxicity, the cell lines utilized in the previous experiments
were transiently co-transfected with the pSV40-Rib21AS-Fluc,
pApoE-Rib21AS-TK, pPEPCK-Rib21AS-TK, or pSV40-
Rib21AS-TK plasmid together with pEGFP-N1 (Fig. 6A). If
ribozymes are well expressed in hTERT-positive cells, the ribo-
zymes can induce activity of 3 0 exon, HSV-tk, through trans-
splicing with the hTERT RNA. After transfection, the cells
were incubated further in medium supplemented with
100 lMGCV for three days and then cell toxicity was assessed
by counting GFP-positive cells (Figs. 6 and 7). We presented
number of GFP-positive cells in the pApo-Rib21AS-TK orby speciﬁc trans-splicing ribozyme derived by liver-speciﬁc promoters.
e expression in each transfectant cell: Hep3B (A); SKOV3 (B); THLE3
ent. The lowest panel of (B) showed representative phase contrasts of
M.-S. Song, S.-W. Lee / FEBS Letters 580 (2006) 5033–5043 5041pPEPCK-Rib21AS-TK transfected cells as the percentage of
those in the mock-transfected cells (Table 3). As shown in
DT assay, the hTERT-targeting ribozyme induced negligible
TK activity in IMR90 or THLE3, irrespective of promoter sys-
tems for its expression (Figs. 6B and 7C). However, the ribo-
zyme induced TK activity eﬃciently, but not selectively, and
hence stimulated cell cytotoxicity with GCV treatment in any
of the telomerase-positive cancer cell lines when expressed
using SV40 promoter (Figs. 6C, 7A,B and Table 3). In sharp
contrast, the ribozyme driven by ApoE or PEPCK promoter
induced cytotoxicity with GCV treatment eﬃciently and selec-
tively in telomerase-positive liver cancers, which level was com-
parable to the cytotoxicity by SV40 promoter-driven ribozyme
(Figs. 6D, 7A, and Table 3). For example, ribozyme expression
using the liver-speciﬁc promoters resulted in the death of 40–
60% of hepatocarcinoma cells, Hep3B, when incubated with
100 lM GCV. However, activity of TK gene by the ribozyme
expressed from the liver-speciﬁc promoters was much less than
the ribozyme from SV40 promoter in non-liver cancer cell
lines, thus the liver-speciﬁc promoter-driven ribozyme
increased a fold of viability of the cells when compared with
SV40 promoter-driven ribozyme (Figs. 6E, 7B, and Table 3).
Especially, cytotoxicity was hardly seen in ovarian, breast,
colon, neuronal, prostate, or cervical cancer cells, or erythro-
leukemia cells when the ribozyme was expressed using the
liver-speciﬁc promoters (Table 3). Therefore, the trans-splicing
ribozyme expressed from the ApoE or PEPCK promoter
induced anti-cancer gene activity in a liver cancer-speciﬁc
manner, which suggests that liver-speciﬁc transcriptional
targeting of trans-splicing ribozyme represent potentially use-
ful for speciﬁc cancer gene therapy.Table 4
GCV sensitivity of each cell line
Cell line Liver cancer (Tel+)
HepG2 Hep3B SNU398
Cell viability (%) 94 ± 17.8 92 ± 14.1 94 ± 9.1
Non-liver cancer (Tel+)
SK-OV-3 MCF7 HT29 ACC
Cell viability (%) 78 ± 19.8 91 ± 12.6 88 ± 25.8 71 ±
The intrinsic sensitivity of each cell line to GCV is measured using 3 · 105 cell
with 100 lMGCV concentration. GFP positive cells in each cell was expresse
means ± S.D.
Table 3
Survival cell percentage by TK-encoding trans-splicing ribozymes after GCV
Vector Liver cancer (Tel+)
HepG2 Hep3B SNU398
pSV40-Rib21AS-TK 47 53 59
pAPO-Rib21AS-TK 76 36 63
pPEPCK-Rib21AS-TK 67 62 97
Non-liver cancer (Tel+)
SK-OV-3 MCF7 HT29
pSV40-Rib21AS-TK 19 81 66
pAPO-Rib21AS-TK 119 109 99
pPEPCK-Rib21AS-TK 111 104 84
The number of GFP-positive cells after transfection with TK-encoding spec
percentage of those with mock transfection and GCV treatment. Values are3.5. Speciﬁc cytotoxicity is not due to intrinsic GCV sensitivity
in cells
It might be possible that the high-level death of the liver can-
cer cell lines by the liver-speciﬁc promoter-driven ribozyme
could be attributable to their intrinsic sensitivity to GCV tox-
icity, not due to TK induction eﬀect via ribozyme expression.
Alternatively, low-level death in non-liver cancers by the spe-
ciﬁc ribozyme from the liver-speciﬁc promoters could be due
to their intrinsic resistance to GCV. To test these possibilities,
the sensitivity of each cell line to 100 lM GCV was measured
by assessing and comparing the cell viability with the cells
incubated without GCV (Table 4). Live cell content was
counted as surviving GFP-positive cells with ﬂuorescence
microscope, and the cell viability was expressed as a percentage
relative to untreated cells. The viability of cells with GCV
treatment was not so much reduced irrespective of cell types
when compared with the cells without GCV, suggesting that
the liver cancer cell lines contain no intrinsic sensitivity to
GCV toxicity. Moreover, eﬃcient decrease in viability was
shown in non-liver cancers with GCV treatment when transfec-
ted with pSV40-Rib21AS-TK (Fig. 6), indicating that low
sensitivity to the GCV treatment in non-liver cells such as
SK-OV-3 cells transfected with ApoE or PEPCK promoter-dri-
ven ribozyme vectors is not due to a high level of resistance to
GCV, but rather low levels of the TK product in the cell lines.4. Discussion
Group I based trans-splicing ribozymes have been developed
for repair of mutant transcripts such as sickle b-globin RNATel Non-tumorigenic liver
SK-Hep-1 IMR90 THLE3
113 ± 17.7 108 ± 8.5 109 ± 8.5
DU145 AGS HeLa TF-1a
17.4 109 ± 14.6 119 ± 38.5 98 ± 21.5 108 ± 8.4
s transfected with pEGFP-N1 in triplicate, which are incubated for 96 h
d as % of those without treatment of GCV. Values were represented as
treatment
Tel Non-tumorigenic liver
SK-Hep-1 IMR90 THLE3
58 107 91
68 100 98
76 101 119
ACC DU145 AGS HeLa TF-1a
13 44 41 31 27
99 102 74 86 101
123 93 79 89 100
iﬁc ribozyme vectors and administered with GCV was presented as a
expressed as means from three to six independent experiments.
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disease [26]. Moreover, the ribozymes have been developed for
therapeutic gene induction via speciﬁc RNA targeting and
replacement of viral RNA [27] or cancer-speciﬁc RNA [17],
and thus could be therapeutically utilized for infectious and
malignant diseases. In our previous studies, we developed a
ribozyme speciﬁcally targeting against the hTERT RNA, and
showed that the expression of functional HSV-tk was selec-
tively stimulated by the ribozyme in the hTERT RNA-express-
ing cancer cells through correct trans-splicing reaction [17].
Therefore, the expression of the hTERT-targeting ribozyme
with TK caused cell cytotoxicity speciﬁcally in the telome-
rase-positive cancer cells with GCV treatment. However, the
expression of transgene by this hTERT-targeting ribozyme
could be not absolutely tumor-speciﬁc since highly proliferat-
ing normal cells, including germ cells and stem cells, will be also
telomerase-positive [28]. In other words, a major limitation of
the ribozyme targeting for hTERT RNA is nonselective toxic
eﬀect on normal cells that express the target RNA.
In this study, we attempted to render the ribozyme more
selective for liver tumor cells and less toxic for normal cells
by use of liver-speciﬁc transcriptional promoter to express
the speciﬁc ribozyme. One of the limitations of these tissue-
speciﬁc promoters is that transgene with the promoters was
not perfectly selectively expressed in liver cancer cell lines
(Fig. 2). In addition, another problem to use the liver-speciﬁc
promoters is that transgene can be highly expressed also in
normal liver cell lines such as THLE3 cells (Fig. 2). Therefore,
expression of therapeutic gene including TK using only the
liver-speciﬁc promoters will cause a serious problem since
the lack of tumor selectivity. In large contrast, tissue-speciﬁc
expression of speciﬁc trans-splicing ribozyme with the liver-
speciﬁc promoters can enhance speciﬁcity of transgene expres-
sion in cancer cells with speciﬁc tissue origin because of target
RNA-speciﬁc inducibility of transgene by the ribozyme cou-
pled with tissue-speciﬁc transgene expression capability by
the tissue-speciﬁc promoter. If cells are expressing hTERT
RNA, the ribozyme can express transgene selectively in the
cells via RNA replacement. In addition, if cells are originated
from liver tissue, liver-speciﬁc promoters can induce transgene
eﬀectively in liver cells. Thus, combination of the trans-splicing
ribozyme and the liver-speciﬁc promoters will more speciﬁcally
induce transgene in the hTERT-positive liver cancer cells. We
have indeed demonstrated in this report that reporter gene
activity was highly stimulated in hTERT-positive liver cancers,
but not in telomerase-positive non-liver cancers including TF-
1a or telomerase-negative IMR90 cells, by expression of the
ribozyme using the liver-speciﬁc promoters such as ApoE or
PEPCK promoter (Fig. 3). Moreover, the ribozyme could
eﬀectively induce cell cytotoxicity in telomerase-positive liver
cancer cells, but not in non-liver cancers, normal liver cell,
or telomerase-negative cells, also when expressed from the
liver-speciﬁc promoters (Figs. 4–7, and Tables 2 and 3).
Noticeably, the absence of toxicity was observed in telome-
rase-positive bone marrow-derived cells (TF-1a) via expression
of the ribozyme using the liver-speciﬁc promoters, which sug-
gests that the approach developed in this study will reduce
any side eﬀects in normal germ cells and/or stem cells which
can be caused by targeting hTERT.
In this study, activity of the liver-speciﬁc promoters was
compared with that of the SV40 promoter that can ubiqui-
tously express transgene in high level [29]. From the experi-ments of reporter gene activation and cell cytotoxicity, the
ApoE and PEPCK promoters are more eﬃciently active in
liver cancer cell lines, which level is comparable to the SV
promoter, than other non-liver cancer cell lines. However,
albumin promoter has limitation for eﬃcient induction of gene
activity even in the liver cells due to low RNA expressional
level in the cell lines tested in this study (data not shown). It
has been previously shown that several other tissue-speciﬁc
promoters can confer tumor-speciﬁc suicide gene expression;
however, high viral vector dose or an increase in GCV concen-
tration accompanied by severe liver toxicity was necessary to
achieve therapeutic eﬀects [30]. As toxicity is a major obstacle
in suicide gene therapy, we wanted to conﬁrm the toxicity and/
or eﬃcacy of the hTERT targeting trans-splicing ribozyme de-
rived by ApoE and PEPCK promoters (Figs. 6,7, and Tables 3
and 4). These data suggest that, at the eﬀective and tolerable
GCV concentrations, the tissue-speciﬁc expression of the ribo-
zyme has the potential to suﬃciently induce liver tumor killing
with reduced toxicity to normal tissue. Therefore, the tissue-
speciﬁc expression of the ribozyme exhibited a lower toxicity
proﬁle (normal cell toxicity) and a higher speciﬁcity (toxicity
of liver cancer cell lines) than the expression of the ribozyme
using SV40 promoter that is a strongly positive regulator of
gene expression but lacks expression speciﬁcity. An additional
drawback of the SV40 promoter derives from the fact that it
represents a viral sequence that is frequently downregulated
in vivo [31]. As a result, ApoE and PEPCK promoters will
be good candidates for cancer gene therapy aiming at speciﬁc
and persistent expression of therapeutic genes in liver tumors,
as described [22,23].
In summary, we have shown in this study a proof of princi-
ple that speciﬁcity of cancer therapy can be enhanced by com-
bination of the tissue-speciﬁc transgene expression using
tissue-speciﬁc promoters with eﬀective tumor-restricted gene
activation using cancer-speciﬁc RNA targeting trans-splicing
ribozyme. Especially, our system used a ribozyme speciﬁcally
targeting the hTERT transcript and the ApoE or PEPCK pro-
moters to express the ribozyme, which can be applied to an
eﬀective and liver tumor-speciﬁc therapeutic approach. More-
over, the modularity of tissue-speciﬁc promoter, speciﬁc RNA-
targeting ribozyme, and therapeutic gene tagged as 3 0 exon of
the ribozyme opens the possibility of restricted induction of
any therapeutic gene activity in any speciﬁc targeted tissues
which express speciﬁc RNA. This concept needs to be further
explored in in vivo studies.
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